查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018714

医药契约製造与研发服务市场：2026-2032年全球市场预测（依服务类型、分子类型、剂型、治疗领域及顾客类型划分）

Pharmaceutical Contract Manufacturing & Research Services Market by Service Type, Molecule Type, Dosage Form, Therapeutic Area, Customer Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，医药契约製造和研发服务市场价值将达到 2,148.7 亿美元，到 2026 年将成长至 2,372 亿美元，到 2032 年将达到 4,440.3 亿美元，复合年增长率为 10.92%。

主要市场统计数据
基准年 2025 2148.7亿美元
预计年份：2026年 2372亿美元
预测年份 2032 4440.3亿美元
复合年增长率 (%) 10.92%

一份策略性产业指南，旨在协调研究重点、製造能力和监管合规性，以加速产品开发并降低商业化风险。

在技​​术创新、监管日益复杂以及战略采购体系重组等多重压力下，医药契约製造和研发服务的格局正在改变。本文重点阐述了领导者最关注的关键问题：如何在加快临床试验速度的同时，确保生产品质和合规性。策略团队必须制定协调一致的蓝图，将早期研究决策与后期生产和商业化路径衔接起来，而不是仅仅追求渐进式改善。

科学的复杂性、数位转型和伙伴关係的重新定义如何重塑整个产业的能力、合约模式和竞争差异化。

生物製药领域正经历着由科学复杂性、数位化和重新定义的伙伴关係模式所驱动的变革。生物製药和先进治疗方法正在推动对专业设施和特定领域专业知识的投资，从而催生了对扩充性、灵活的生产平台的需求。同时，数位化品质系统、即时分析和预测性维护的采用正在改变营运预期，并提升契约製造的资产利用率。

我们评估不断变化的关税趋势如何促使企业做出策略采购、供应商多元化和在地化生产决策，以确保供应的连续性。

美国关税政策已成为供应链规划、筹资策略和服务交付成本计算的关键变数。近期关税调整的累积影响促使企业重新评估供应商选址、原料采购和库存布局，更重视供应链的韧性而非短期成本套利。因此，企业正在权衡集中式低成本采购与跨国分散式供应链（以降低关税波动风险）之间的利弊。

详细的细分洞察，将每种服务类型的特征和最终用户的优先顺序与供应商选择标准、合约设计和营运风险缓解措施连结起来。

根据服务类型和最终用户的不同，细分市场的特定趋势决定了投资、能力和策略重点的分配方向。基于服务类型，企业可以利用咨询服务，专注于品质保证和法规咨询，以应对复杂的核准流程，并使内部流程与外部合作伙伴的能力相符。在生产服务方面，原料药生产、生技药品生产和製剂生产需要差异化评估。製剂需求进一步细分为液体製剂、半固态製剂和固态製剂，每种製剂都需要独特的製程管制和包装的考量。研究服务涵盖生物分析服务、临床研究服务、药物发现、临床前研究和毒性测试，每个环节都对资料完整性、样本处理和分析验证有特定的要求。

在全球主要地区，地理采购选择如何影响研发和製造专案的监管策略、生产力计画和韧性优先事项？

区域趋势持续影响采购选择、监管策略和产能投资，并以特定方式影响供应韧性和专业能力的取得。在美洲，强大的临床试验能力和成熟的法规环境支持着快速研发项目和一体化研发产量模式，而供应商网络仍集中在规模优势和完善品质系统的特定中心。同时，在欧洲、中东和非洲（EMEA）地区，管理体制和卓越研究中心较为分散，迫使企业在获取先进生技药品专业知识与应对多司法管辖区核准和物流相关的行政复杂性之间寻求平衡。

深入了解供应商差异化和合作伙伴选择，并专注于整合能力、数位品质系统和已验证的技术转移记录。

如今，供应商必须展现其在研发、监管和生产等各个环节的跨职能能力，因此，企业的能力和策略定位比以往任何时候都更加重要。主要企业透过整合服务组合、投资数位化品质体係以及在技术转移和监管沟通方面的卓越业绩来脱颖而出。这些供应商也在投资培养能够连接科学开发和程式工程的人才，从而实现从实验到商业化生产的平稳过渡。同时，专注于特定领域的专家则吸引了那些需要专业问题解决方案而非广泛生产能力的客户，他们提供特定领域的深厚专业知识，并为新型生物製药和复杂製剂提供客製化的开发支援。

为加速内部管治结构重组、供应商多元化以及做好数位化和监管合规准备，提出切实可行的跨职能建议，以确保专案稳健执行。

行业领导企业应采取一系列切实可行的措施，使其内部结构与外部供应商的能力以及不断变化的地缘政治现实相匹配。首先，他们应组成跨职能团队，涵盖采购、研发、法规事务和品质保证等部门，从统一的观点评估供应商机会，兼顾科学需求和营运实际情况。其次，他们应优先考虑与那些能够快速技术转移、具备多地点生产能力以及拥有可记录的监管合作经验的供应商建立合作关係，以缩短实施时间并降低检查风险。第三，他们应投资建立内部数位化品管和资料完整性系统，以促进整合并实现对外包活动的即时监控。

采用透明的多来源调查方法，结合专家访谈、监管审查和情境分析，来检验策略和营运影响。

本分析的研究途径结合了对行业趋势的跨学科审查、对各领域专家的定性访谈，以及对公开监管指南和企业资讯披露的系统整合。主要资讯来源包括与製造业企业领导者、监管事务专家和研发主管的讨论，以检验观察到的趋势，并从多个角度分析其对采购、设施投资和产能发展的影响。二级资讯来源包括科学文献、监管指南文件和企业技术手册，以确保观察结果基于检验的实践和政策。

结论是透过策略伙伴关係、能力投资和积极主动的供应链韧性措施，将复杂性转化为优势。

总之，受治疗方法日益复杂、数位化进步以及贸易格局变化等因素驱动，医药契约製造与研发服务生态系统正处于策略转捩点。认识到研发决策、供应商能力和监管准备之间相互依存关係的机构，将更有利于在保证品质和合规性的同时加速研发进程。为实现此目标，领导者必须超越单纯的交易型采购模式，采用包含责任共用、一体化规划和能力透明化的伙伴关係模式。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：医药契约製造与研发服务市场：依服务类型划分

  • 原料药生产
  • 製药生产
  • 包装和整理
  • 发展服务
  • 临床试验服务
  • 检验和测试服务
    • 品管和出货检验
    • 稳定性测试
    • 生物分析和微生物检测

第九章：按分子类型分類的製药契约製造与研发服务市场

  • 低分子化合物
  • 生物製药
  • 先进治疗方法

第十章：以剂型分類的药品契约製造与研发服务市场

  • 口服固态剂型
  • 口服液
  • 吸入/鼻喷剂
  • 眼药水

第十一章：医药契约製造与研发服务市场：依治疗领域划分

  • 肿瘤学
  • 循环系统/新陈代谢
  • 中枢神经系统
  • 感染疾病
  • 免疫学/炎症
  • 呼吸系统
  • 消化系统和肝臟
  • 皮肤科
  • 眼科
  • 罕见疾病/孤儿

第十二章：医药契约製造与研发服务市场：依客户类型划分

  • 大型製药企业
  • 中型製药公司
  • 新兴虚拟製药公司
  • 生物技术
  • 学名药生产商
  • 非处方药生产商
  • 消费者健康营养保健品公司
  • 学术机构和非营利组织

第十三章：医药契约製造与研发服务市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：医药契约製造与研发服务市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：药品契约製造与研发服务市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国製药契约製造与研发服务市场

第十七章：中国医药契约製造与研发服务市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc
  • Almac Group
  • Amanta Healthcare Ltd.
  • Aragen Life Sciences Ltd.
  • Automatic Liquid Packaging Solutions LLC
  • Baxter Pharmaceutical Solutions LLC
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc
  • Curida AS
  • Dalton Pharma Services
  • Evonik Industries AG
  • Famar Group
  • Horizon Pharmaceuticals, Inc
  • Laboratorios SALVAT, SA
  • Lonza Group Ltd.
  • Nephron Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Recipharm AB
  • Rommelag SE & Co. KG
  • Rusoma Laboratories Private Limited
  • Silgan Unicep
  • Unither Pharmaceuticals SAS
  • UPM Pharmaceuticals, Inc.
  • Woodstock Sterile Solutions
Product Code: MRR-AD36CD898497

The Pharmaceutical Contract Manufacturing & Research Services Market was valued at USD 214.87 billion in 2025 and is projected to grow to USD 237.20 billion in 2026, with a CAGR of 10.92%, reaching USD 444.03 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 214.87 billion
Estimated Year [2026] USD 237.20 billion
Forecast Year [2032] USD 444.03 billion
CAGR (%) 10.92%

A strategic industry primer that aligns research priorities, manufacturing capability, and regulatory readiness to accelerate development and de-risk commercialization

The pharmaceutical contract manufacturing and research services landscape is evolving under the simultaneous pressures of technological innovation, regulatory complexity, and strategic sourcing realignments. This introduction frames the single most important consideration for leaders: the need to reconcile speed to clinic with manufacturing quality and regulatory robustness. Strategic teams must move beyond incremental improvements and adopt coordinated road maps that link early research decisions with late-stage manufacturing and commercialization pathways.

Across the continuum, organizations face converging disruptions. Advanced biologics platforms raise the bar for facility design and workforce competency, while digitalization of quality systems promises efficiency gains but requires disciplined change management. As a result, partnerships with external service providers are shifting from transaction-based engagements to outcome-driven collaborations. This change influences internal governance, supplier scorecards, and the structure of commercial agreements.

Consequently, executives should treat contract manufacturing and research services as integral components of product strategy rather than outsourced line items. By aligning procurement, R&D, and regulatory affairs early, companies can reduce downstream surprises and accelerate program delivery. The remainder of this executive summary builds on that premise, offering insight into strategic shifts, tariff-related headwinds, segmentation-specific implications, regional differentiators, and pragmatic recommendations for leaders ready to act.

How scientific complexity, digital transformation, and partnership redefinition are reshaping capabilities, contracting, and competitive differentiation across the industry

The sector is undergoing transformative shifts driven by scientific complexity, digital enablement, and redefined partnership models. Biotherapeutics and advanced modalities have prompted investments in specialized facilities and niche expertise, which in turn have created demand for scalable, flexible manufacturing platforms. Meanwhile, the adoption of digital quality systems, real-time analytics, and predictive maintenance is changing operational expectations and enabling higher asset utilization across contract manufacturing organizations.

At the same time, life science organizations are rethinking relationships with external suppliers, moving from one-off orders to integrated alliances that encompass joint development, co-investment in capacity, and shared risk models. This transition favors providers with cross-functional capabilities in research, regulatory support, and multiphase manufacturing. Consequently, procurement professionals and R&D leaders are increasingly focused on a provider's ability to deliver end-to-end solutions and to demonstrate regulatory compliance across jurisdictions.

Finally, talent and culture are becoming competitive differentiators. Organizations that successfully combine scientific depth with process engineering expertise and digital fluency will lead. Therefore, stakeholders should prioritize capability audits and partner assessments that evaluate not only technical performance but also adaptability and governance structures. These shifts require companies to update decision frameworks, contracting approaches, and internal competencies to secure reliable, future-proof supply and research pathways.

Assessing how evolving tariff dynamics are prompting strategic sourcing, supplier diversification, and localized manufacturing decisions to safeguard supply continuity

Tariff policy in the United States has emerged as a consequential variable for supply chain planning, procurement strategies, and cost-to-serve calculations. The cumulative effects of recent tariff adjustments have prompted organizations to reassess supplier footprints, raw material sourcing, and inventory positioning in ways that emphasize resilience over short-term cost arbitrage. As a result, firms are evaluating trade-offs between consolidated low-cost sourcing and diversified multi-jurisdictional supply chains that reduce exposure to tariff volatility.

These adjustments have downstream impacts on lead times, supplier qualification cycles, and demand for local manufacturing or tolling arrangements. Companies that previously relied heavily on single-country suppliers now face longer qualification timelines when onboarding alternate providers, creating a strong incentive to engage early with contract manufacturing partners that offer multi-country manufacturing footprints or validated secondary suppliers. Simultaneously, procurement teams are expanding their remit to include trade policy monitoring and tariff scenario planning as routine inputs to supplier negotiations.

Importantly, regulatory compliance and quality standards remain non-negotiable amid tariff-driven reshoring or nearshoring initiatives. Consequently, firms should prioritize partners capable of rapid technology transfer and regulatory dossier updates. In the near term, organizations that integrate tariff risk into sourcing strategies, supplier scorecards, and contingency playbooks will improve continuity of supply and protect development timelines despite ongoing external trade pressures.

Detailed segmentation insights that link service type specificity and end-user priorities to supplier selection criteria, contractual design, and operational risk mitigation

Segment-specific dynamics shape where investments, capabilities, and strategic priorities should land across service types and end-users. Based on service type, organizations are engaging consulting services that focus on quality assurance consulting and regulatory consulting to navigate complex approval pathways and to align internal processes with external partner capabilities. Manufacturing services demand differentiated assessment across API manufacturing, biologics manufacturing, and finished dosage form manufacturing, with finished dosage form needs further divided into liquid formulations, semi-solid formulations, and solid formulations, each requiring distinct process controls and packaging considerations. Research services span bioanalytical services, clinical research services, drug discovery, preclinical research, and toxicology studies, and each node in that chain imposes specific data integrity, sample handling, and analytical validation requirements.

Based on end-user, stakeholders include academic and government research institutes that prioritize translational capabilities and reproducibility; biotechnology companies that emphasize speed, platform flexibility, and specialized biologics capacity; and pharmaceutical companies that require scale, global regulatory experience, and integrated supply solutions. The intersection of service type and end-user profile drives supplier selection criteria: companies seeking accelerated clinical timelines will favor research providers with deep bioanalytical and clinical trial operations, while mature pharmaceutical firms will assess manufacturing partners for global regulatory track record and high-volume capacity. Therefore, segmentation insight points to the need for tailored contracting frameworks, capability verification protocols, and integrated risk assessments that reflect the unique technical and commercial contours of each service-end-user pairing.

How geographic sourcing choices across major global regions influence regulatory strategy, capacity planning, and resilience priorities for development and manufacturing programs

Regional dynamics continue to influence sourcing choices, regulatory strategy, and capacity investments with distinct implications for supply resilience and access to specialized capabilities. In the Americas, strength in clinical trial capacity and a mature regulatory ecosystem supports rapid development programs and integrated development-manufacturing pathways, while supplier networks remain concentrated in select hubs that offer scale and established quality systems. Conversely, Europe, Middle East & Africa presents a patchwork of regulatory regimes and centers of excellence, where companies must balance access to advanced biologics expertise with the administrative complexity of multi-jurisdictional approvals and logistics.

Across the Asia-Pacific region, manufacturing capacity and skilled process development talent have expanded rapidly, offering cost-efficient production alternatives and specialized biologics experience; however, organizations must carefully evaluate supplier compliance history and data integrity practices. Transitioning between regions requires robust technology transfer protocols, harmonized quality agreements, and a clearly defined plan for regulatory filings and inspection readiness. Taken together, regional insight underscores the importance of aligning geographic sourcing strategies with product modality, regulatory timelines, and corporate resilience objectives to achieve operational continuity and strategic flexibility.

Insights on provider differentiation and partnership selection that emphasize integrated capabilities, digital quality systems, and proven technology transfer track records

Company capabilities and strategic positioning matter more than ever when providers must demonstrate cross-functional delivery across research, regulatory, and manufacturing domains. Leading firms differentiate through integrated service portfolios, investments in digital quality systems, and proven track records in technology transfer and regulatory interactions. These providers also invest in talent that bridges scientific development and process engineering, enabling smoother scale-up from bench to commercial output. Conversely, niche specialists offer deep modality expertise and bespoke development support for novel biologics or complex formulations, attracting clients that require specialized problem-solving rather than broad-scale capacity.

Partnership selection should therefore prioritize demonstrable end-to-end capabilities, transparent quality metrics, and governance mechanisms that support joint accountability. Strategic considerations include a provider's ability to mobilize cross-site resources, to maintain validated supply chains for critical raw materials, and to support regulatory submissions across major jurisdictions. In addition, firms demonstrating robust digitalization roadmaps and real-world evidence capabilities are increasingly valuable for programs that demand agility and data-driven decision making. Ultimately, company-level insight points to the need for rigorous due diligence frameworks that assess operational readiness, financial stability, and cultural fit to ensure long-term program success.

Practical, cross-functional recommendations to realign internal governance, diversify suppliers, and accelerate digital and regulatory readiness for resilient program delivery

Industry leaders should pursue a set of actionable steps that align internal structures with external provider capabilities and evolving geopolitical realities. First, integrate cross-functional teams that include procurement, R&D, regulatory affairs, and quality assurance to evaluate supplier opportunities through a unified lens that balances scientific needs with operational realities. Second, prioritize partnerships with providers that can demonstrate rapid technology transfer, multi-site manufacturing footprints, and documented regulatory interactions to reduce onboarding timelines and inspection risk. Third, invest in digital quality and data integrity systems internally to smooth integrations and to enable real-time oversight of outsourced activities.

Beyond these immediate actions, firms should develop supplier diversification playbooks that account for tariff volatility and logistics disruptions, and they should build scenario-based contingency plans that are exercised regularly. Leadership should also elevate talent strategies that retain critical scientific and process expertise while fostering collaboration skills necessary for effective external partnerships. Finally, allocate resources to targeted audits and joint development pilots that validate capabilities before committing to long-term volume contracts. Taken together, these recommendations enable leaders to convert strategic intent into operational resilience and to sustain competitive advantage amid a changing industry landscape.

Transparent, multi-source research methodology combining expert interviews, regulatory review, and scenario analysis to validate strategic and operational implications

The research approach for this analysis combined a multi-disciplinary review of industry developments, qualitative interviews with subject matter experts, and structured synthesis of publicly available regulatory guidance and corporate disclosures. Primary inputs included discussions with manufacturing leaders, regulatory affairs specialists, and R&D executives to validate observed trends and to triangulate implications for sourcing, facility investment, and capability development. Secondary sources encompassed scientific literature, regulatory agency guidance documents, and company technical briefs to ground observations in verifiable practice and policy.

Analysis prioritized the identification of practical implications rather than quantitative projections, focusing on capability gaps, operational bottlenecks, and governance approaches that affect program timelines and supplier selection. Data integrity, reproducibility, and regulatory readiness were assessed through a combination of expert validation and documentary review. Where applicable, scenario analysis was applied to explore the operational consequences of tariff shifts and supplier concentration, and findings were stress-tested against stakeholder feedback to ensure robustness. This methodology emphasizes transparency and applicability so that recommendations can be adapted to specific organizational contexts and decision priorities.

Concluding perspective on turning complexity into advantage through strategic partnerships, capability investments, and proactive supply chain resilience measures

In closing, the pharmaceutical contract manufacturing and research services ecosystem is at a strategic inflection point driven by modality complexity, digital adoption, and shifting trade dynamics. Organizations that recognize the interdependence of research decisions, supplier capabilities, and regulatory preparedness will be better positioned to accelerate development while preserving quality and compliance. To achieve this, leaders must move beyond transactional sourcing and adopt partnership models that embed shared accountability, integrated planning, and capability transparency.

Moreover, regional nuances and tariff-driven supply chain adjustments require proactive scenario planning and supplier diversification to protect program timelines. Finally, investment in talent, digital quality systems, and rigorous due diligence processes will determine which organizations can successfully translate external partnerships into sustained operational performance. By acting decisively on these imperatives, stakeholders can convert uncertainty into structured opportunity and establish a durable advantage in a rapidly evolving industry.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmaceutical Contract Manufacturing & Research Services Market, by Service Type

  • 8.1. Drug Substance Manufacturing
  • 8.2. Drug Product Manufacturing
  • 8.3. Packaging & Finishing
  • 8.4. Development Services
  • 8.5. Clinical Trial Services
  • 8.6. Laboratory & Testing Services
    • 8.6.1. Quality Control & Release Testing
    • 8.6.2. Stability Studies
    • 8.6.3. Bioanalytical & Microbiology Testing

9. Pharmaceutical Contract Manufacturing & Research Services Market, by Molecule Type

  • 9.1. Small Molecules
  • 9.2. Biologics
  • 9.3. Advanced Therapies

10. Pharmaceutical Contract Manufacturing & Research Services Market, by Dosage Form

  • 10.1. Oral Solid
  • 10.2. Oral Liquid
  • 10.3. Inhalation & Nasal
  • 10.4. Ophthalmic

11. Pharmaceutical Contract Manufacturing & Research Services Market, by Therapeutic Area

  • 11.1. Oncology
  • 11.2. Cardiovascular & Metabolic
  • 11.3. Central Nervous System
  • 11.4. Infectious Diseases
  • 11.5. Immunology & Inflammation
  • 11.6. Respiratory
  • 11.7. Gastrointestinal & Hepatology
  • 11.8. Dermatology
  • 11.9. Ophthalmology
  • 11.10. Rare Diseases & Orphan

12. Pharmaceutical Contract Manufacturing & Research Services Market, by Customer Type

  • 12.1. Large Pharma
  • 12.2. Mid-Sized Pharma
  • 12.3. Emerging & Virtual Pharma
  • 12.4. Biotech
  • 12.5. Generic Drug Companies
  • 12.6. Over-The-Counter Drug Companies
  • 12.7. Consumer Health & Nutraceutical Companies
  • 12.8. Academic & Non-Profit Sponsors

13. Pharmaceutical Contract Manufacturing & Research Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pharmaceutical Contract Manufacturing & Research Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pharmaceutical Contract Manufacturing & Research Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Pharmaceutical Contract Manufacturing & Research Services Market

17. China Pharmaceutical Contract Manufacturing & Research Services Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc
  • 18.6. Almac Group
  • 18.7. Amanta Healthcare Ltd.
  • 18.8. Aragen Life Sciences Ltd.
  • 18.9. Automatic Liquid Packaging Solutions LLC
  • 18.10. Baxter Pharmaceutical Solutions LLC
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. Cambrex Corporation
  • 18.13. Catalent, Inc
  • 18.14. Curida AS
  • 18.15. Dalton Pharma Services
  • 18.16. Evonik Industries AG
  • 18.17. Famar Group
  • 18.18. Horizon Pharmaceuticals, Inc
  • 18.19. Laboratorios SALVAT, S.A
  • 18.20. Lonza Group Ltd.
  • 18.21. Nephron Pharmaceuticals Corporation
  • 18.22. Pfizer, Inc.
  • 18.23. Recipharm AB
  • 18.24. Rommelag SE & Co. KG
  • 18.25. Rusoma Laboratories Private Limited
  • 18.26. Silgan Unicep
  • 18.27. Unither Pharmaceuticals SAS
  • 18.28. UPM Pharmaceuticals, Inc.
  • 18.29. Woodstock Sterile Solutions

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DRUG PRODUCT MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DRUG PRODUCT MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DRUG PRODUCT MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY PACKAGING & FINISHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY PACKAGING & FINISHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY PACKAGING & FINISHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DEVELOPMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DEVELOPMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DEVELOPMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CLINICAL TRIAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CLINICAL TRIAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CLINICAL TRIAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY QUALITY CONTROL & RELEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY QUALITY CONTROL & RELEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY QUALITY CONTROL & RELEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY STABILITY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY STABILITY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY STABILITY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOANALYTICAL & MICROBIOLOGY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOANALYTICAL & MICROBIOLOGY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOANALYTICAL & MICROBIOLOGY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ADVANCED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ADVANCED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ADVANCED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ORAL SOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ORAL SOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ORAL SOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ORAL LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ORAL LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY INHALATION & NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY INHALATION & NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY INHALATION & NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OPHTHALMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CARDIOVASCULAR & METABOLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CARDIOVASCULAR & METABOLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CARDIOVASCULAR & METABOLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GASTROINTESTINAL & HEPATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GASTROINTESTINAL & HEPATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GASTROINTESTINAL & HEPATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY RARE DISEASES & ORPHAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY RARE DISEASES & ORPHAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY RARE DISEASES & ORPHAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MID-SIZED PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MID-SIZED PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MID-SIZED PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY EMERGING & VIRTUAL PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY EMERGING & VIRTUAL PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY EMERGING & VIRTUAL PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GENERIC DRUG COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GENERIC DRUG COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GENERIC DRUG COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OVER-THE-COUNTER DRUG COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OVER-THE-COUNTER DRUG COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY OVER-THE-COUNTER DRUG COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CONSUMER HEALTH & NUTRACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CONSUMER HEALTH & NUTRACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CONSUMER HEALTH & NUTRACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ACADEMIC & NON-PROFIT SPONSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ACADEMIC & NON-PROFIT SPONSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY ACADEMIC & NON-PROFIT SPONSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 178. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 180. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 181. GCC PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 201. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 202. G7 PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 208. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 209. NATO PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY LABORATORY & TESTING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING & RESEARCH SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)